Zhi Xiang Jintai: Signed the Authorization and Commercialization Agreement for GR1803 Injectable Solution with Cullinan

Zhixiang Jintai announced that the company has signed an authorization and commercialization agreement with Cullinan, and the two parties will collaborate in the development and commercialization of GR1803 injection in the Greater China region for the treatment of moderate to severe active rheumatoid arthritis. According to the agreement, the company will receive exclusive licensing from Cullinan to develop, manufacture, and commercialize GR1803 injection in the Greater China region. Zhixiang Jintai will make upfront and milestone payments to Cullinan, and will also pay a certain percentage of franchise royalties based on net sales.